Revatio

Description

Revatio (sildenafil)

Background
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death (1-2). Revatio received approval on May 26, 2009 for treatment of pulmonary arterial hypertension (PAH) which is classified by WHO as Group 1 (1). Revatio is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the lungs) to improve the exercise ability (1). Sildenafil, at different dosages, is also marketed as Viagra for the treatment of erectile dysfunction which is a plan exclusion (1).

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

WHO Group 1: Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic (IPAH)
1.2 Heritable PAH
   1.2.1 Germline mutations in the bone morphogenetic protein receptor type 2 (BMPR2)
   1.2.2 Activin receptor-like kinase type 1 (ALK1), endoglin (with or without hereditary hemorrhagic telangiectasia), Smad 9, caveolin-1 (CAV1), potassium channel super family K member-3 (KCNK3)
   1.2.3 Unknown
1.3 Drug-and toxin-induced
1.4 Associated with:
   1.4.1 Connective tissue diseases
   1.4.2 HIV infection
   1.4.3 Portal hypertension
   1.4.4 Congenital heart diseases (e.g. pulmonary artresia)
   1.4.5 Schistosomiasis
1'. Pulmonary vena-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
1". Persistent pulmonary hypertension of the newborn (PPHN)

**WHO Group 2: Pulmonary Hypertension Owing to Left Heart Disease**

2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies

**WHO Group 3: Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia**

3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities

**WHO Group 4: Chronic Thromboembolic Pulmonary Hypertension <CTEPH>**

**WHO Group 5: Pulmonary Hypertension with Unclear Multifactorial Mechanisms**

5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher's disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH
The American College of Chest Physicians (ACCP) has published an updated clinical practice guideline for treating PAH. These guidelines use the New York Heart Association (NYHA) functional classification of physical activity scale to classify PAH patients in classes I-IV based on the severity of their symptoms. Revatio is indicated for patients with NYHA Functional Class II and III symptoms (3).

**ADULT NYHA FUNCTIONAL CLASS CHART**

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class II</td>
<td>Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class III</td>
<td>Patients with pulmonary hypertension resulting in marked limitation of physical activity. These patients are comfortable at rest, but less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class IV</td>
<td>Patients with pulmonary hypertension resulting in inability to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at rest, and discomfort is increased by any physical activity.</td>
</tr>
</tbody>
</table>

**CHILDRENS NYHA FUNCTIONAL CLASS CHART**

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Asymptomatic</td>
</tr>
<tr>
<td>Class II</td>
<td>Mild tachypnea or diaphoresis with feeding in infants. Dypnea on exertion in older children</td>
</tr>
<tr>
<td>Class III</td>
<td>Marked tachypnea or diaphoresis with feeding in infants. Marked dyspnea on exertion. Prolonged feeding times with growth failure</td>
</tr>
<tr>
<td>Class IV</td>
<td>Symptoms such as tachypnea, retractions, grunting, or diaphoresis at rest</td>
</tr>
</tbody>
</table>

These guidelines recommend that oral therapy with a phosphodiesterase inhibitor (sildenafil) be used as first-line therapy for NYHA Class II and III patients (3). Revatio (sildenafil) is the same therapeutic class as Adcirca (tadalafil) and has the same indication for PAH (WHO group 1).

**Regulatory Status**

FDA-approved indication: Revatio is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominately
patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (primary) pulmonary hypertension (71%) or pulmonary hypertension associated with connective tissue disease (25%) (1).

**Off Label Uses:**
Revatio may be used off label for the treatment of Raynaud’s syndrome. In this syndrome patients experience temperature-sensitive digital vasospasm leading to cyanotic skin, usually in the digits. Sildenafil increases the capillary blood flow velocity in patients with therapy-resistant Raynaud’s syndrome (6).

Revatio may be used off label for the treatment of pediatric with PAH. PDE5 expression and activity are increased in PAH and specific PDE5 inhibitors such as sildenafil or tadalafil increase smooth muscle cell cGMP levels and promote pulmonary vascular dilation and remodeling in pediatric patients (5).

The use of Revatio is contraindicated in patients who are using any form of organic nitrate, either regularly or intermittently. Revatio potentiates the hypotensive effect of nitrates. This potentiation is thought to result from the combined effects of nitrates and Revatio on the nitric oxide/cGMP pathway (1). Revatio is also contraindicated with riociguat (1).

The efficacy of Revatio has not been adequately evaluated in patients taking bosentan concurrently. Revatio, particularly for chronic use, is not recommended in children (1).

**Related policies**
Adcirca, Adempas, Flolan/Veletri, Letairis, Opsumit, Orenitram, Remodulin, Tracleer, Tyvaso, Uptravi, Ventavis

**Policy**
This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Revatio may be considered **medically necessary** for the treatment of patients with pulmonary arterial hypertension, WHO Group I and if the conditions indicated below are met.

Revatio may be considered **medically necessary** in patients with Raynaud’s syndrome and if the conditions indicated below are met.

Revatio may be considered **investigational** for patients with all other indications.
Prior-Approval Requirements

Diagnoses

Patient must have ONE of the following

1. Pulmonary Arterial Hypertension - WHO Group I
   a. NYHA functional classification of physical activity - Class II or III

2. Raynaud’s syndrome
   a. Inadequate treatment response, intolerance, or contraindication to TWO of the following:
      i. Calcium channel blockers
      ii. Alpha adrenergic receptor blockers
      iii. Angiotensin II receptor antagonist

   AND NONE of the following:
   1. Concurrent therapy with any nitrates (in any form)
   2. Concurrent therapy with riociguat
   3. Concurrent therapy with another phosphodiesterase - 5 (PDE5) inhibitor

Prior – Approval Renewal Requirements

Diagnoses

Patient must have ONE of the following

1. Pulmonary Arterial Hypertension - WHO Group I

2. Raynaud’s syndrome

AND the following:

1. Symptoms have improved or stabilized

AND NONE of the following:

2. Concurrent therapy with any nitrates (in any form)
3. Concurrent therapy with riociguat
4. Concurrent therapy with another phosphodiesterase - 5 (PDE5) inhibitor
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death. Revatio is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening (1). Revatio may also be used off label for treatment therapy-resistant Raynaud’s syndrome (4).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Revatio while maintaining optimal therapeutic outcomes.

References
5.40.11

Section: Prescription Drugs  
Effective Date: October 1, 2019

Subsection: Cardiovascular Agents  
Original Policy Date: November 1, 2009

Subject: Revatio  
Page: 7 of 7

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2009</td>
<td>The FDA has approved Revatio (sildenafil, from Pfizer) injection, an intravenous phosphodiesterase-5 (PDE-5) inhibitor, for the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening. Revatio injection is for the continued treatment of patients with PAH who are currently prescribed Revatio tablets but who are temporarily unable to take oral medication. Revatio injection will be available in a single-use vial. Revatio tablets are already available in 20mg dosage strength.</td>
</tr>
<tr>
<td>December 2009</td>
<td>Both PDE5 inhibitors are indicated for the treatment of PAH WHO group 1, NYHA class II, III, or IV. Patients taking tadalafil or sildenafil may see an improvement in NYHA class that could prevent them from qualifying for prior approval renewal. Studies show evidence of improvements in functional class (NYHA class), usually one class jump only; such as from class II to class I. Renewal requirements have been modified to allow continuation of therapy for patients who were previously NYHA Class II for tadalafil or sildenafil, but whose condition has improved on therapy to NYHA Class I.</td>
</tr>
<tr>
<td>September 2012</td>
<td>The U.S. Food and Drug Administration (FDA) recommends that Revatio (sildenafil) not be prescribed to children (ages 1 through 17) for pulmonary arterial hypertension (PAH; high pressure in the blood vessels leading to the lungs).</td>
</tr>
<tr>
<td>March 2013</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>March 2014</td>
<td>Annual review</td>
</tr>
<tr>
<td>September 2014</td>
<td>Line addition of Revatio oral recon suspension</td>
</tr>
</tbody>
</table>
| March 2015 | Annual editorial review and reference update  
Addition of no concurrent therapy with phosphodiesterase inhibitors.  
Removal of Nitrate examples |
| April 2016 | Removal of NYHA class IV symptoms, addition of no concurrent therapy with riociguat, addition of therapy resistant Raynaud’s syndrome  
Policy number change from 5.16.06 to 5.40.11 |
| June 2016 | Annual editorial review and reference update |
| September 2017 | Annual review and reference update |
| November 2017 | Addition of Children’s NYHA functional class chart |
| March 2018 | Annual review |
| September 2019 | Annual editorial review and reference update. Changed approval duration from lifetime to 2 years |

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 13, 2019 and is effective on October 1, 2019.